Literature DB >> 2444869

Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro: visualization of chain elongation on a defined template.

A J Townsend1, Y C Cheng.   

Abstract

1-beta-D-arabinofuranosyl-5-aza-cytosine (ara-5-aza-Cyd) is an analog of 1-beta-D-arabinofuranosylcytosine (ara-C), which resembles ara-C in anabolic metabolism, incorporation into DNA, and inhibition of DNA replication. Human T-lymphoblastic cells (Molt-4) incorporate three- to fivefold more ara-5-aza-Cyd than ara-C into DNA during 5-8 hr exposure. Although ara-5-aza-Cyd and its triphosphate metabolite are unstable in aqueous solution, the aza-analog was much more stable in solution when incorporated into native DNA isolated from Molt-4 cells. By using gapped duplex DNA as a substrate for purified human DNA polymerases alpha and beta, inhibition of [3H]-dCTP incorporation by ara-5-aza-CTP and ara-CTP was competitive, with Ki values for alpha of 11 and 1.5 microM, respectively. Ki values for polymerase beta were 39 and 7.6 microM, respectively. A DNA elongation assay was adapted from DNA sequencing technology, using singly primed bacteriophage M13mp19 or M13mp9 (+)-DNA. Elongation of 5'-[32P]-labeled primer by polymerase alpha is slowed considerably by incorporation of one ara-CMP and to a lesser extent after incorporation of one ara-5-aza-CMP. Neither analog significantly affected elongation by polymerase beta after a single incorporation. However, neither polymerase alone could appreciably extend the growing chain if two consecutive ara-5-aza-CMP or ara-CMP analogs were incorporated. Thus, if similar mechanisms are operant in intact cells, the greater incorporation of ara-5-aza-Cyd than ara-C into DNA may be due to a more facile elongation of the nascent DNA strand by polymerase alpha after incorporation of a single analog. The effect in vitro of incorporation of either analog on DNA chain elongation is widely variable, depending on the identity of the polymerase involved and the sequence of the DNA template being copied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444869

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.

Authors:  D D Ross; D P Cuddy; N Cohen; D R Hensley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.

Authors:  M C Starnes; Y C Cheng
Journal:  Virus Genes       Date:  1989-05       Impact factor: 2.332

3.  A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and -resistant leukemic cells.

Authors:  L P Colly; D J Richel; W Arentsen-Honders; I W Starrenburg; P M Edelbroek; R Willemze
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.

Authors:  H Zhao; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Authors:  B Chandrasekaran; T E Kute; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Development of novel inhibitor probes of DNA polymerase III based on dGTP analogs of the HPUra type: base, nucleoside and nucleotide derivatives of N2-(3,4-dichlorobenzyl)guanine.

Authors:  M M Butler; L W Dudycz; N N Khan; G E Wright; N C Brown
Journal:  Nucleic Acids Res       Date:  1990-12-25       Impact factor: 16.971

7.  Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate.

Authors:  R L Heideman; C McCully; F M Balis; D G Poplack
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  RNase H activity associated with reverse transcriptase from feline immunodeficiency virus.

Authors:  R C Cronn; J D Whitmer; T W North
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Biological effects of a relatively low concentration of 1-beta-D-arabinofuranosylcytosine in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

Authors:  H Yamada; J Horiguchi-Yamada; M Nagai; S Takahara; T Sekikawa; T Kawano; K Itoh; S Fukumi; S Iwase
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

Review 10.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.